View Cancer Clinical Trials
Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
|North Coast Cancer
- To determine the 1-year overall survival rate in patients with ED-SCLC with the administration of PCI alone versus PCI with consolidation extracranial RT following platinum based chemotherapy
- To compare treatment-related adverse events;
- To evaluate patterns of failure;
- To compare the time to first failure;
- To evaluate the percentage of the planned radiation dose given to each site.
- Pathologically (histologically or cytologically) proven diagnosis of extensive disease small cell lung cancer without brain metastases and with 1-4 metastatic lesions; Note: This does NOT include patients initially diagnosed with LD-SCLC who have progressed.
- Patients must have completed 4-6 cycles of platinum-based chemotherapy.
- Patients must be registered on study within 8 weeks of completing chemotherapy.
- Prior to chemotherapy (at diagnosis), patients must have extensive stage disease with 1-4 extracranial metastatic lesions (no brain metastases). For example, the patient could have 2 lesions in the liver and 2 in the contralateral lung; or 1 in the bone, 1 in the contralateral lung, and 2 in the liver; or 3 liver lesions and 1 in the bone, etc. Lesion is not defined as "organ". The patient should have no clinical signs or symptoms of CNS metastases. Brain imaging is not
required prior to chemotherapy if the patient is asymptomatic; however, brain imaging is
required and must be negative for metastases prior to study entry. Extent of disease will be based on the following minimum diagnostic workup:
- History/physical examination;
- CT of the chest and abdomen with contrast or PET/CT.
- After chemotherapy, patients will be restaged using the following diagnostic work up :
Patients must have:
- History/physical examination;
- CT of the chest and abdomen with contrast (does not have to be done if the patient has had a PET/CT scan within 8 weeks prior to registration);
- Bone scan (does not have to be done if the patient has had a PET scan within 8 weeks prior to registration);
- MRI of the brain or CT with contrast of the brain, if MRI is contraindicated.
- no CNS metastases;
- radiographic partial or complete response to chemotherapy in a minimum of 1 site of disease using RECIST criteria (see Section 11.3.2); Note: if radiation has been delivered to primary disease with chemotherapy, there must be complete or partial response in at least 1 of the sites that has not been treated with radiation.
- no progression in any site;
- for the purposes of stratification, a response to treatment is only considered a “CR” if the patient has had a complete response in all sites of measurable disease.
- Patients who have had thoracic radiation concurrently or prior to chemotherapy for the current diagnosis and meet all other eligibility criteria are eligible for the study but will not receive mediastinal radiation per protocol.
- Measurements for all pre- and post-chemotherapy measurable disease must be submitted.
- Zubrod Performance Status 0-2;
- Age ≥ 18;
- For patients who will be treated with radiation to the liver, adequate hepatic function, defined as follows:
- Serum ALT and AST within 2.5 X ULN within 1 week prior to registration;
- Serum bilirubin < 1.5 X ULN within 1 week prior to registration.
- For patients who will be treated with radiation to the kidneys, adequate renal function defined as a serum creatinine < 1.5 X ULN within 1 week of registration;
- CBC/differential obtained within 1 week prior to registration, with adequate bone marrow function defined as follows:
- Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3;
- Platelets ≥ 75,000 cells/mm3;
- Hemoglobin ≥ 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable.).
- For women of childbearing potential, a negative serum pregnancy test within 1 week of registration;
- All toxicities related to chemotherapy must be resolved to < grade 1 prior to initiation of study therapy (with the exception of neuropathy and alopecia, which may take a longer period to recover). Laboratory abnormalities, with the exception of those specified in Sections 3.1.9, 3.1.10, and 3.1.11, are allowed if they are not deemed clinically significant.
- Patients must provide study-specific informed consent prior to study entry.
- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields (see Section 3.1.6 for exception);
- Limited stage disease at diagnosis;
- Central nervous metastases;
- Severe, active co-morbidity, defined as follows:
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;
- Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
- Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
Cancer Answers & Appointments
Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.
Monday through Friday from 8 a.m. – 4:30 p.m. (ET).
Resources for medical professionals
- Outpatient appointment referrals: 216.444.7923 or 866.223.8100
- Inpatient hospital transfers: 800.553.5056
- Referring Physician Concierge: 216.444.6196 or 216.312.4910.
Search available cancer clinical trials by disease, hospital, phase or number.
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2015 Cleveland Clinic. All rights reserved.